Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
122M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
7.16M
-
Shares change
-
-67.7K
-
Total reported value, excl. options
-
$15.8M
-
Value change
-
+$2.08M
-
Number of buys
-
12
-
Number of sells
-
-7
-
Price
-
$2.20
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q1 2022
23 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q1 2022.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.16M shares
of 122M outstanding shares and own 5.89% of the company stock.
Largest 10 shareholders include TPG GP A, LLC (4.82M shares), MAI Capital Management (1.54M shares), VANGUARD GROUP INC (153K shares), RENAISSANCE TECHNOLOGIES LLC (116K shares), WealthTrust Axiom LLC (98.5K shares), MILLENNIUM MANAGEMENT LLC (84.9K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (75K shares), GEODE CAPITAL MANAGEMENT, LLC (72.7K shares), STATE STREET CORP (36.8K shares), and BlackRock Inc. (33.4K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.